INNOVADERM CRO IS NOW INDERO.

Discover 8 Types of Adaptive Designs in Clinical Trials

Diane Potvin

Diane Potvin

Senior Statistical Advisor

Author picture

Adaptive design is paving the way for more efficient and flexible studies. We are thrilled to present 8 types of adaptive designs that are shaping this transformation.

  • Group sequential
    Allows for one of more pre-planned interim analyses and incorporates predetermined criteria for adaptations.
  • Adaptation to the sample size
    Allows pre-planned adjustments to the sample size based on results from interim analyses.
  • Adaptation to the patient population
    Allows for adjustments to the patient population based on results from interim analyses. For instance, following results from interim analyses, enrolment could be restricted to a specific subpopulation.
  • Adaptations to treatment arm selection
    Allows for pre-planned modifications of treatment arms based on results from interim analyses (adding or terminating arms).
  • Seamless phase 2/3
    Design that integrates both Phase 2 and Phase 3 components within the same trial. The transition from Phase 2 and Phase 3 is conducted without interruption.
  • Adaptations to patient allocation
    Allows for adjustments to allocation of subjects to treatment group based on accumulating data during the trial.
  • Adaptation to endpoint selection
    Allows for adjustments to the selection of the primary endpoint based on results from interim analyses.
  • Adaptation to multiple design features
    Combines several adaptive designs.

Click here to download the PDF version.

For a comprehensive understanding, we recommend reading the full article available:  Potvin D, D’Angelo P, Bennett S, Jankicevic J, Bissonnette R. Adaptive designs in dermatology clinical trials: Current status and future perspectives. J Eur Acad Dermatol Venereol. 2024 Apr 15. doi: 10.1111/jdv.20030. Epub ahead of print. PMID: 38619384.

 

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.